Mayne Pharma signs up deals to market Subacap in Europe

12 August 2013

Australian drugmaker Mayne Pharma (ASX: MYX) says it has signed two marketing and distribution agreements for Subacap, an improved formulation of itraconazole used to treat fungal infections, in four key European pharmaceutical markets.

Spain-based Isdin, a leading dermatology company in Southern Europe, will market the product in Spain, Italy and Portugal. India-headquartered Glenmark will do likewise in the UK. Under the two exclusive distribution agreements, Mayne will receive upfront payments, milestone payments on meeting certain market launch hurdles, and a percentage of net sales in each country. Mayne will manufacture the product for both distributors at its facility in South Australia.

Product launch is expected to occur by the end of calendar 2013 in the UK, early 2014 for Spain and by the end of 2014 for Italy and Portugal following a “repeat use” procedure to extend the existing marketing authorization into those additional countries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK